This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	TTK protein kinase (TTK; MPS1); PTEN (MMAC1; TEP1); AarF domain containing kinase 2 (ADCK2); estrogen receptor	An <i>in vitro</i> study suggests inhibiting TTK could help treat PTEN-deficient breast cancer and inhibiting ADCK2 could help treat estrogen receptor (ER)-positive breast cancer. In breast cancer cell lines treated with a small molecule TTK inhibitor, PTEN deficiency led to less proliferation than PTEN expression. In breast cancer cell lines treated with small interfering RNA against ADCK2, ER-positive cell lines showed less survival than ER-negative cell lines. Next steps could include testing the effects of blocking TTK and ADCK2 in mouse models of breast cancer.	Patent and licensing status unavailable	Brough, R. <i>et al. Cancer Discov.</i> ; published online Aug. 2, 2011; doi:10.1158/2159-8290.CD-11-0107 Contact: Alan Ashworth, The Institute of Cancer Research, London, U.K. e-mail: alan.ashworth@icr.ac.uk Contact: Christopher J. Lord, same affiliation as above e-mail: Chris.Lord@icr.ac.uk
<i>SciBX</i> 4(33); doi:10.1038/scibx.2011.926 Published online Aug. 25, 2011				